A Study to Investigate the Procoagulant Effect of Tenecteplase (TNK-tPA), Alteplase (Rt-PA) and Streptokinase (SK) Administered to Patients With Acute Myocardial Infarction (AMI)

Inclusion Criteria: * Onset of symptoms of AMI within 6 hours from randomisation * A twelve-lead electrocardiogram (ECG) showing ST-segment elevation ≥ 0.1 millivolt (mV) in two or more limb leads, or ≥ 0.2 mV in two or more contiguous precordial leads indicative of AMI, or new left bundle-branch block * Age ≥ 18 Exclusion Criteria: * Hypertension defined as blood pressure \> 180/110 mmHg (systolic BP \> 180 mmHg and/or diastolic BP \> 110 mmHg) on repeated measurements during current admission prior to randomisation * Use of abciximab (ReoPro®) within the preceding 7 days or eptifibatide (Integrilin®) or tirofiban (aggrastat®) within the past 48 hours * Use of heparin within the preceding 12 hours * Current therapeutic oral anticoagulation * Major surgery, biopsy of a parenchymal organ, or significant trauma within 2 months * Any minor head trauma and any other trauma occurring after the onset of the current myocardial infarction * Any known history of stroke or transient ischemic attack or dementia * Any known structural damage of the central nervous system * Ruptured aortic aneurism * Active bleeding * Prolonged cardiopulmonary resuscitation (\> 10 minutes) in the previous two weeks * Pregnancy or lactation, parturition within the previous 30 days. Women of childbearing potential must have a negative pregnancy test * Any known active participation in another investigative drug study or device protocol in the past 30 days * Previous enrolment in this study * Any other condition that the investigator feels would place the patient at increased risk if the investigational therapy were initiated * Inability to follow the protocol and comply with follow-up requirements